CURRENT PLACE OF METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article deals with the mechanisms of insulin resistance as the pathogenetic basis of type 2 diabetes and the role of metformin in its treatment. Authors discuss the clinical and molecular effects of the drug with an emphasis on antioxidant and cardioprotective mechanisms of action. Modern data on the importance of side effects and contraindications to metformin is presented. New clinical capabilities of its application and theoretical basis for the testimony to them are considered.

Full Text

Restricted Access

About the authors

Lyudmila Viktorovna Nedosugova

I.M. Sechenov First Moscow State Medical University; Municipal clinical hospital № 67

Email: profmila@mail.ru
MD, Professor of the Department of Endocrinology of the Institute of Professional Education 2007-2009 National Health Interview Survey. http://www.cdc.gov/nchs/nhis.htm

References

  1. World Health Organization: The World health report 1998. Life in 21st century - a vision for ALL. Geneva: World Health Organization, 1998.
  2. IDF Global guideline for managing older people with type 2 diabetes 2013: www.idf.org
  3. Алгоритмы специализированной медицинской помощи больным сахарным диабетом под ред. И.И. Дедова, М.В. Шестаковой. 7-й выпуск. Москва, 2015.
  4. Hsueh W.A., Law R.E. Cardiovascular risk continuum: Implications of insulin resistance and diabetes. Am. J. Med. 1998;105:4S-14S.
  5. Ланкин В.З., Лисина М.О., Арзамасцева Н.Е., Коновалова Г.Г., Недосугова Л.В., Каминный А.И., Тихазе А.К., Агеев Ф.Т., Кухарчук В.В., Беленков Ю.Н. Окислительный стресс при атеросклерозе и диабете. Бюллетень экспериментальной биологии и медицины. 2005;140(1):41-3.
  6. -2009 National Health Interview Survey. http://www.cdc.gov/nchs/nhis.htm
  7. Coutinho M., Gerstein H.C., Wang Y., Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22:233-40.
  8. Giannarelli R., Aragona M., Coppelli A., Del Prato S. Reducing insulin resistance with metformin: the evidence today. Diabetes Metab. 2003;29:6S28-6S35.
  9. Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J. Diabetes. 2015;6(3):456-80.
  10. Sinha Roy R., Bergeron R., Zhu L. Metformin is a GLP-1 secretagogue, not a dipeptidyl peptidase-4 inhibitor. Diabetologia. 2007;50(suppl 1):S284.
  11. Hirst J.A., Farmer A.J., Ali R., Roberts N.W., Stevens R.J. Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care. 2012 ;35(2):446-54.
  12. DeFronzo R.A., Stonehouse A.H., Han J., Wintle M.E. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet. Med. 2010;7:309-17.
  13. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-65.
  14. Saenz A., Fernandez-Esteban I., Mataix A., Ausejo M., Roque M., Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2005;CD002966.
  15. Standl E., Schnell O. Alpha-glucosidase-inhibitors 2012 - cardiovascular considerations and trial evaluation. Diabetes Vasc. Dis. Res. 2012;9:163-9.
  16. Deacon C.F. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes. Metab. 2011;13:7-18.
  17. Musso G., Gambino R., Cassader M., Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann. Med. 2012;44:375-93.
  18. Sherifali D., Nerenberg K., Pullenayegum E., Cheng J.E., Gerstein H.C. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care. 2010;33(8):1859-645.
  19. Mearns E.S., Sobieraj D.M., White C.M., Saulsberry W.J., Kohn C.G., Doleh Y., Zaccaro E., Coleman C.I. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis. PLoS One. 2015;10(4):e0125879.
  20. Lasserson D.S., Glasziou P., Perera R., Holman R.R., Farmer A.J. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia. 2009;52:1990-2000.
  21. Donnelly L.A., Doney A.S., Hattersley A.T., Morris A.D., Pearson E.R. The effect of obesity on glycaemic response to metformin or sulphonylureas in type 2 diabetes. Diabet. Med. 2006;23:128-33.
  22. Rodriguez-Moctezuma J.R., Robles-Lopez G., Lopez-Carmona J.M., Gutiérrez-Rosas M.J. Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes. Diabetes Obes. Metab. 2005;7:189-92.
  23. Genuth S. The UKPDS and its global impact. Diabet. Med. 2008;25:57-62.
  24. Farshad Forouzandeh D.P., Salazar G., Patrushev N., Xiong S., Hilenski L., Fei B., Wayne Alexander R. Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis. J. Am. Heart Assoc. 2014;3(6):e001202.
  25. Ланкин В.З., Тихазе А.К., Беленков Ю. Н. Свободнорадикальные процессы при заболеваниях сердечно-сосудистой системы. Кардиология. 2000;40(7):48-61.
  26. Ohira M., Miyashita Y., Ebisuno M., Saiki A., Endo K., Koide N., Oyama T., Murano T., Watanabe H., Shirai K. Effect of metformin on serum lipoprotein lipase mass levels and LDL particle size in type 2 diabetes mellitus patients. Diabetes Res. Clin. Pract. 2007;78(1):34-41.
  27. Недосугова Л.В. Возможные механизмы антиатеросклеротического эффекта Глюкофажа. Сахарный диабет. 2006;3:6-9.
  28. Beisswenger P., Ruggiero-Lopez D. Metformin inhibition of glycation processes. Diabetes Metab. 2003;29(4 Pt 2) :6S95-103.
  29. Baynes J.W., Thorpe S.R. Glycoxidation and lipoxidation in atherogenesis. Free Radic. Biol. Med. 2000;28:1708-16.
  30. Beisswenger P., Howell S., Smith K., Szwergold B. Glyceraldehyde-3-phosphate dehydrogenase activity as an independent modifier of methylglyoxal levels in diabetes. Biochim. Biophys. Acta. 2003;1637:98-106.
  31. Isoda K., Young J.L., Zirlik A., MacFarlane L.A., Tsuboi N., Gerdes N., Schönbeck U., Libby P. Metformin inhibits proinflammatory responses and nuclear factor-kappa B in human vascular wall cells. Arterioscler. Thromb. Vasc. Biol. 2006;26(3):611 -7.
  32. Grant P.J. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab. 2003;29:6S44-6S52.
  33. Diabetes prevention program research group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002;346:393-403.
  34. Levri K.M., Slaymaker E., Last A., Yeh J., Ference J., D'Amico F., Wilson S.A. Metformin as treatment for overweight and obese adults: a systematic review. Ann. Fam. Med. 2005;3:457-61.
  35. Dyson J., Day C. Treatment of non-alcoholic fatty liver disease. Dig. Dis. 2014;32(5):597-604.
  36. Balen A.H., Rutherford A.J. Managing anovulatory infertility and polycystic ovary syndrome. BMJ. 2007;335:663-6.
  37. Gandini S., Puntoni M., Heckman-Stoddard B.M., Dunn B.K., Ford L., DeCensi A., Szabo E. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev. Res. (Phila). 2014;7(9):867-85.
  38. Hardie D.G. The AMP-activated protein kinase pathway - new players upstream and downstream. J. Cell Sci. 2004;117:5479-87.
  39. Papanas N., Maltezos E., Mikhailidis D.P. Metformin and heart failure: never say never again. Expert Opin. Pharmacother. 2012;1:1-8.
  40. Inzucchi S.E., Lipska K.J., Mayo H., Bailey C.J., McGuire D.K. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312(24):2668-75.
  41. Salpeter S.R., Greyber E., Pasternak G.A., Salpeter E.E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2010;4:CD002967.
  42. Jager J., Kooy A., Lehert P., Wulffelé M.G., van der Kolk J., Bets D., Verburg J., Donker A.J., Stehouwer C.D. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B12 deficiency: randomised placebo controlled trial. BMJ. 2010;340:c2181.
  43. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009;32:193-203.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies